Optimization of GPR40 Agonists for Type 2 Diabetes

[Image: see text] GPR40 (FFA1 and FFAR1) has gained significant interest as a target for the treatment of type 2 diabetes. TAK-875 (1), a GPR40 agonist, lowered hemoglobin A1c (HbA1c) and lowered both postprandial and fasting blood glucose levels in type 2 diabetic patients in phase II clinical tria...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Liu, Jiwen (Jim), Wang, Yingcai, Ma, Zhihua, Schmitt, Mike, Zhu, Liusheng, Brown, Sean P., Dransfield, Paul J., Sun, Ying, Sharma, Rajiv, Guo, Qi, Zhuang, Run, Zhang, Jane, Luo, Jian, Tonn, George R., Wong, Simon, Swaminath, Gayathri, Medina, Julio C., Lin, Daniel C.-H., Houze, Jonathan B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Chemical Society 2014
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027784/
https://ncbi.nlm.nih.gov/pubmed/24900872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml400501x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia